357 related articles for article (PubMed ID: 15902620)
21. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
22. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
24. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
25. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
26. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
Yoon SS; Tanabe KK
Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951
[No Abstract] [Full Text] [Related]
27. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
28. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
29. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
30. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
[No Abstract] [Full Text] [Related]
31. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
[No Abstract] [Full Text] [Related]
32. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
34. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
36. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
37. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
38. Kinases as targets in the treatment of solid tumors.
Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]